EUCTR2005-002626-59-SE进行中（未招募）不适用
A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy - Premenopausal Endocrine Responsive Chemotherapy Trial (PERCHE)
International Breast Cancer Study Group (IBCSG)0 个研究点目标入组 1,750 人开始时间: 2005年7月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Premenopausal women (estradiol (E2) in the premenopausal range (per institution parameters) following surgery; the only patients who do not require testing of estradiol (E2) to confirm premenopausal status are those who have been menstruating regularly during the 6 months prior to randomization and have not used any form of hormonal contraception or any other hormonal treatments during the 6 months prior to randomization). Patients should be randomized within 12 weeks after definitive surgery.
- •Histologically proven, resected breast cancer. Pathology material should be available for submission for central review as part of the quality control measures for this protocol.
- •Patients must have hormone receptor positive tumors. If there is more than one breast tumor,each tumor must be hormone receptor positive. Hormone receptors must be determined using immunohistochemistry. ER and/or PgR must be greater than or equal to 10% of the tumor cells positive by immunohistochemical evaluation. Biochemical determination alone is not acceptable
- •The tumor must be confined to the breast and axillary nodes without detected metastases elsewhere, with the exception of tumor detected in internal mammary chain nodes by sentinel node procedure.
- •Patients must have had proper surgery for primary breast cancer with no known clinical residual loco-regional disease.
- •A total mastectomy. Radiotherapy is optional after mastectomy.
- •A breast-conserving procedure (lumpectomy, quadrantectomy or partial mastectomy with margins clear of invasive cancer and DCIS). The local pathologist must document negative margins of resection in the pathology report. If all other margins are clear, a positive posterior (deep) margin is permitted, provided the surgeon documents that the excision was performed down to the pectoral fascia and all tumor has been removed. Likewise, if all other margins are clear, a positive anterior (superficial; abutting skin) margin is permitted provided the surgeon documents that all tumor has been removed. Radiation therapy to the conserved breast is required.
- •Either axillary lymph node dissection (pathological examination of at least 6 nodes recommended) or a negative axillary sentinel node biopsy [pN0(sn)] is required. Patients with negative or microscopically axillary positive sentinel nodes (pN1mi: micrometastasis none >2.0mm) do not require further axillary therapy. Those with positive sentinel nodes must have either an axillary dissection or radiation of axillary nodes.
- •For IBCSG centers, patients must have completed baseline Quality of Life (QL) Forms prior to randomization. The only exceptions are cognitive or physical impairment that interferes with QL assessment or inability to read any of the languages available on IBCSG QL forms. For non-IBCSG centers, extent of participation in the QL study is to be determined at the activation of the trial for each cooperative group.
- •Written informed consent must be signed and dated by the patient and the investigator prior to randomization.
- •Patients must be accessible for follow-up.
- •Patients must be informed of and agree to data and tissue material transfer and handling, in accordance with national data protection guidelines
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who are postmenopausal (i.e, do not have an estradiol (E2) level in the premenopausal range) after surgery.
- •Patients with distant metastatic disease.
- •Patients with locally advanced inoperable breast cancer including inflammatory breast cancer or supraclavicular node involvement or with enlarged internal mammary nodes (unless pathologically negative) are not eligible. Patients with involved internal mammary nodes detected by sentinel node biopsy that are not enlarged are eligible.
- •Patients with positive final margins (referring to only DCIS and invasive cancer, not LCIS), except as noted in section 3.1.5. DCIS at a margin is permitted if a complete mastectomy has been performed.
- •Patients with clinically detectable residual axillary disease.
- •Patients with a history of prior ipsilateral or contralateral invasive breast cancer. Patients with synchronous bilateral invasive breast cancer (diagnosed histologically within 2 months) are eligible if the bilateral disease meets all other eligibility criteria.
- •Patients with previous or concomitant invasive malignancy EXCEPT adequately treated:
- •- basal or squamous cell carcinoma of the skin
- •- in situ non-breast carcinoma without invasion
- •- contra- or ipsilateral in situ breast carcinoma
- •- non-breast invasive malignancy diagnosed at least 5 years ago and without recurrence: stage I papillary thyroid cancer, stage Ia carcinoma of the cervix, stage Ia or b endometrioid endometrial cancer, borderline or stage I ovarian cancer
- •Patients with other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung, etc.) that would prevent prolonged follow-up. Patients with previous deep venous thrombosis (e.g., DVT) and/or embolism can be included only if medically suitable.
- •Patients who have had a bilateral oophorectomy or ovarian irradiation.
- •Patients with a history of noncompliance to medical regimens and patients who are considered potentially unreliable.
- •Patients who are pregnant or lactating at the time of randomization or who desire a pregnancy within 5 years. Patients planning to use additional hormonal therapy apart from the randomized treatment during the next five years including all types of hormonal contraception. A pregnancy test is recommended for women of child-bearing potential who are sexually active and not using reliable contraceptive methods.
- •Patients who received any neoadjuvant or adjuvant endocrine therapy after their breast cancer diagnosis.
- •Patients who were taking tamoxifen or other SERM (e.g. Raloxifene) or hormone replacement therapy (HRT) within one year prior to their breast cancer diagnosis. Prior oral contraceptives are allowed.
- •Patients who received any neoadjuvant or adjuvant chemotherapy. Neoadjuvant or adjuvant trastuzumab (Herceptin) is allowable, as it is not considered to be chemotherapy for eligibility determination.
- •Patients with psychiatric, addictive, or any disorder that would prevent compliance with protocol requirements.
研究者
相似试验
进行中（未招募）
不适用
A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy - Premenopausal Endocrine Responsive Chemotherapy Trial (PERCHE)Premenopausal women with histologically proven, resected breast cancer with ERand/or PgR positive tumors for whom there is an uncertain role for adding chemotherapy to the adjuvant treatment programMedDRA version: 7.0Level: LLTClassification code 10057654EUCTR2005-002626-59-DEGBG Forschung GmbH1,750
进行中（未招募）
1 期
A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as pre-operative treatment for locally recurrent rectal cancer (GRECCAR – PRODIGE – FRENCH) - GRECCAR 15Recurrent rectal cancer after local excision, Rectal cancerMedDRA version: 20.0Level: PTClassification code: 10038038Term: Rectal cancer Class: 100000004864CTIS2024-514705-62-00Centre Hospitalier Universitaire De Bordeaux186
招募中
3 期
A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as pre-operative treatment for locally recurrent rectal cancer (GRECCAR – PRODIGE – FRENCH) - GRECCAR 152024-514705-62-00Centre Hospitalier Universitaire De Bordeaux186
尚未招募
3 期
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical HysterectomyCTRI/2019/04/018382RG National Research Group Oncology
已完成
不适用
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By SurgeryPER-155-08EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),